Navigation Links
Potential new drugs plug brain's biological 'vacuum cleaner' and target HIV

In an advance toward eliminating pockets of infection in the brain that help make HIV disease incurable, scientists report the development of new substances that first plug the biological vacuum cleaner that prevents anti-HIV drugs from reaching the brain and then revert to an active drug to treat HIV. They describe the advance, which allows medications to cross the so-called "blood-brain barrier" (BBB) and treat brain diseases, in the Journal of the American Chemical Society.

Jean Chmielewski, Christine Hrycyna and colleagues explain that Human Immunodeficiency Virus infection remains incurable because HIV can sneak through the BBB -- a network of special blood vessels and cells that protects the brain from many harmful substances -- while many of the most powerful anti-viral medications cannot. A pump at the BBB suctions anti-viral medicines away like a biological vacuum cleaner, leaving a reservoir of HIV in the brain. To overcome this hurdle and get rid of the last footholds of HIV, the researchers set out to develop a new group of drugs that can plug up the vacuuming mechanism and then sneak across the BBB to fight HIV.

Their approach involves gluing two anti-HIV drug molecules together with a "tether." This dual drug plugs up the BBB vacuum cleaner and can then sneak across the BBB. Once across, the tether disintegrates, freeing the two drug molecules to kill the virus. "This overall strategy represents a platform technology that may be readily applied to other therapies with limited brain penetration," such as anticancer and anti-schizophrenia drugs, say the researchers.

Contact: Michael Bernstein
American Chemical Society

Page: 1

Related biology news :

1. UI researchers find potentially toxic substance present in Chicago air
2. Scientists from Granada find a potential treatment to prevent diabetes and obesity
3. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
4. Simple chemical procedure augments therapeutic potential of stem cells
5. Chemist to donate potential pharmaceutical royalties to Madagascar
6. Duke study pinpoints potential green collar job growth in US
7. Researchers recreate SARS virus, open door for potential defenses against future strains
8. First trial in patients with a potential treatment of the incurable ALS muscle disease
9. Epilepsy drug shows potential for Alzheimers treatment
10. In just 5 years, gene discovery to clinical trial of potential treatment
11. UC Davis team refines cancer treatments to reduce potential nerve damage
Post Your Comments:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... Paris Police Prefecture and ... ensure the safety of people and operations in several locations ... Teleste, an international technology group specialised in broadband ... its video security solution will be utilised by ... across the country. The system roll-out is scheduled for the ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology: